Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

Inclusion Criteria: * Men, women of non childbearing potential or women of child bearing potential who either abstain from sexual intercourse, have a sterile partner or practice a medically approved double barrier method of contraception * Diagnosis of acromegaly of pituitary origin * Have age adjusted Insulin like Growth Factor 1 (IGF-1) concentrations ≥1.5 times the upper limit of normal range on two consecutive measurements in the 6 months prior to the first dosing day (including the measurement to be made at screening \[Visit 2\]) * Have a random hGH level of ≥5 µg/L in the 6 months prior to or at screening (Visit 2) * Have given written informed consent * Ability to comply with the requirements of the protocol of the study Exclusion Criteria: * Previous specific treatment for acromegaly in the 6 months prior to screening (Visit 2), including somatostatin analogues (SSAs), surgery, radiotherapy and pegvisomant * Treatment with dopamine agonists in the 3 months prior to screening (Visit 2) * Uncontrolled hypertension or orthostatic hypotension * Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated haemoglobin \[HbA1c\]≥7.5%) and patients requiring insulin treatment * Gallstones or gravel that could cause biliary obstruction * Hyperprolactinaemia * Participation in a clinical study within 60 days prior to screening (Visit 2) * Receipt of blood, blood products or plasma derivatives 60 days prior to screening (Visit 2) * Pregnancy or lactation * A history of active alcohol abuse or drug addiction * Positive viral serology screening result for hepatitis B surface antigen, antibodies to hepatitis C virus, or human immunodeficiency virus type 1 and 2 * Evidence or suspicion of tumour expansion * Clinically significant abnormality in screening ECG * Any clinically significant abnormal laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the Investigator * Any disease which in the Investigator's opinion would exclude the patient from the study